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The elucidation of drug resistance mechanisms is very important in the development of 
clinical therapies for the treatment of leukemia. To study the drug resistance 
mechanisms, protein expression profiles of 1-β-D-arabinofuranosylcytosine (AraC) 
sensitive K562 (K562S) cells and AraC resistant K562 (K562AC) cells were compared 
using two-dimensional fluorescence difference gel electrophoresis. In comparison of 
protein expression profiles, 2073 protein spots were found to be altered, 15 proteins of 
them were remarkably altered. These proteins were identified by mass spectrometry. 
The most differently expressed proteins were aldehyde dehydrogenase 1 family member 
A2 (ALDH1A2) and vimentin. Both proteins were verified using reverse transcriptase 
polymerase chain reaction (RT-PCR) and Western blot analysis. ALDH1A2 protein was 
found to be effective in AraC resistance. ALDH1A2 knock down (KD) induced 
sensitivity to AraC treatment in K562AC cells, and ALDH1A2 overexpressed K562S 
cells acquired the AraC resistance. Further, the findings also suggest that ALDH1A2 
expression is increased after the appearance of AraC resistance in clinical cases. These 






Chemotherapy has been very useful in the treatment of leukemia. However, cellular 
drug resistance is the greatest impediment to successful treatment. The mechanism of 
drug resistance can roughly be divided into two processes: drug uptake or metabolism, 
and inhibition of apoptotic cell death or increased repair of drug-induced DNA damage 
[1, 2]. 
Cytosine arabinoside (1-β-D-arabinofuranosylcytosine, AraC) is one of the most 
effective drugs in the chemotherapeutic treatment of acute myeloid leukemia (AML) [3]. 
AraC is also active against other hematologic malignancies such as acute lymphoblastic 
leukemia (ALL) and non-Hodgkin's lymphoma [4]. Laboratory investigations to 
elucidate the biochemical correlation between drug action and drug resistance 
mechanisms have extensively examined the clinical importance of AraC, in order to 
obtain leads for the development of better therapeutic strategies. 
AraC is converted into its active metabolite, cytosine arabinoside triphosphate 
(Ara-CTP), intracellularly in leukemic blasts by deoxycytidine kinase (dCK) [5]. 
Ara-CTP is generally considered to be the active form of the drug since it both inhibits 
DNA polymerase and leads to AraC incorporation into DNA [6]. AraC is catabolized to 
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the non-toxic metabolite, arabinosideuridine (AraU), by a rapid deamination mediated 
by cytidine deaminase (CDD) [7, 8]. Various biochemical mechanisms of AraC 
resistance have been shown in experimental animal tumor models or in vitro systems [9]. 
Low AraC phosphorylation or low dCK in marrow blasts has been associated with poor 
response [10]. It has also been reported that AraC resistance is induced when the influx 
of AraC is reduced because of the human equilibrative nucleoside transporter 1 
(hENT1) [11], when the degradation of AraC is enhanced or when there is excessive 
conversion of AraC to inactive AraU due to high levels of CDD [12]. Although 
multidrug resistance (MDR1) gene and multidrug resistance-associated protein (MRP) 
gene are commonly involved in drug resistance, both the genes have not been observed 
in AraC resistant cells [13]. Various studies have been performed to elucidate the 
mechanism of AraC resistance, but it still remains unexplained.  
Therefore, the present study aimed at investigating the expression of proteins 
associated with the acquisition of resistance to AraC. The expression of the proteins was 
examined using two-dimensional fluorescence difference gel electrophoresis 





Materials and Methods 
Cell Culture 
Human leukemia cell lines, K562S and K562AC, were obtained from the School of 
Medicine, Tohoku University. The resistant clones, termed K562/AC, were established 
and grown for 3 months, during which they were continuously exposed to increasing 
concentrations of Ara-C up to 50 mM, and were maintained in medium containing 
Ara-C. K562AC cells were established before, as described by Funato et al [13].  
K562S cells were confirmed to be sensitive to AraC and K562AC cells were confirmed 
to be resistant to Ara-C (Nihon Shinyaku Co., Japan). The cells were grown in 
RPMI-1640 medium (Nissui Pharmaceutical Co., Japan) with 10% fetal calf serum 
(Cellect, OH, USA) at 37°C in 5% CO2. Doxorubicin resistant derivative of K562 cell 
line was obtained from JCRB Japan, and maintained in medium containing Doxorubicin 
(Wako Co., Japan). 
Cell Viability Assay 
Cell viability was determined by the MTT assay method, using CellTiter 96 AQueous 
Cell Proliferation Assay (Promega, Madison, USA). A total of 10
4
 cell lines were plated 
in each well of a 48-well tissue culture plate. At the indicated times, cell viability was 
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measured. Untreated cells served as control. The viability of treated cells was calculated 
as a percentage of viability relative to the untreated control cells. 
2D-DIGE 
Cell pellets were dissolved in lysis buffer (7M urea, 2 M thiourea, 1% Triton X-100, 4% 
CHAPS, and 10 mM Tris). Cell lysates were labeled with Cy2, Cy3, and Cy5, according 
to the protocols described in the Ettan DIGE user manual (18-1164-40 Edition AA, GE 
Healthcare). The 2 Dimensional Fluorescence Difference Gel Electrophoresis (DIGE) 
was performed according to the method previously reported [14] with some 
modifications. IPG strips (24 cm, pH 3–10 nonlinear, GE) and Ettan IPGphor System 
(GE Healthcare, Uppsala, Sweden) were used for the first-dimension IEF. After 2-DE, 
gels were scanned on Typhoon 9410 scanner (GE Healthcare, Uppsala, Sweden) using 
the Ettan DALT gel alignment guides. 
Gel Imaging and Statistical Analysis 
Gel images were cropped using ImageQuant TL 2003 (GE Healthcare, Uppsala, 
Sweden) and spot detection was performed with DeCyder 6.5 DIA (Difference In-gel 
Analysis) software (GE Healthcare, Uppsala, Sweden). The gel images were matched 
using DeCyder 6.5 BVA (Biological Variation Analysis) software (GE Healthcare, 
Uppsala, Sweden). Statistical analysis was performed using paired Student’s t-test with 
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false discovery rate correction using DeCyder 6.5 BVA. A p<0.05 was considered 
statistically significant. 
For protein identification, individual spots were digested with trypsin. Molecular 
mass analyses of triptic peptides were performed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) using an 
ultraflex TOF/TOF (Bruker Daltonics). Proteins were identified by comparison between 
the molecular weights determined by MALDI-TOF/MS and theoretical peptide masses 
from the proteins registered in NCBInr [15].  
RNA Extraction and semi-quantitative analysis of RT-PCR products 
Total RNA was isolated from cell lines with Isogen (Nippon Gene, Tokyo, Japan) and 
the RNA concentration was determined spectrophotometrically at 260 nm. Reverse 
transcription-PCR was performed using ReverTra Ace qPCR RT Kit (Toyobo, Tokyo, 
Japan). The following PCR primers were synthesized:  
Vimentin forward: 5’-TGTTGACAATGCGTCTCTGGCAC-3, reverse: 
5’-ACTCCAGTCCGAACCTTTGTAGG-3’,  




GAPDH forward: 5’-GCCAAGGTCATCCATGACAAC-3’, reverse: 
5’-AGTGTAGCCCAAGATGCCCTT-3’. Semi-quantitative analysis of RT-PCR 
products was performed by using NIH ImageJ 1.34s software and normalized to 
GAPDH. Shown were the results of one of three expresiments with similar results. 
Western Blot 
Cell extracts were prepared in lysis buffer [100 mM Tris-HCL (pH 8.0), 100 mM NaCl, 
0.5% NP40, and 0.2 mM phenylmethanesulfonyl fluoride], and centrifuged for five 
minutes at 1800 x g at 4°C. The supernatant was collected for protein analysis. Proteins 
in the supernatant were lysed with SDS-PAGE sample buffer, sonicated, and boiled. The 
protein samples were then separated by one-dimensional SDS-PAGE, transferred onto a 
PVDF membrane, and blotted with the appropriate antibodies. The immunoblot signals 
were normalized by the corresponding -actin signal. Antibodies used for Western blot 
analysis were anti-vimentin polyclonal antibody (pAb), anti-ALDH1A2 monoclonal 
antibody (mAb), and anti-GAPDH pAb. Anti-vimentin pAb and anti-ALDH1A2 mAb 
were obtained from Abcam (Cambridge, UK) and anti-GAPDH pAb was obtained from 
Santa Cruz Biotechnology (CA, USA). 
ALDH1A2 constructs and gene transfection. 
10 
 
We used RT-PCR to synthesize the full length cDNA for human ALDH1A2 
(NM_170696). Total RNA was extracted from K562AC cells and used for the synthesis 
of the cDNAs. Full-length human ALDH1A2 cDNAs were subcloned into the 
N-terminus venus-tagged CAGGS expression vector. ALDH1A2 gene transfection to 
K562S cells was performed using Lipofectamine Plus (Invitrogen, Carlsbad, CA), 
following the manufacturer’s instructions. To establish stable transfectants, transfected 
cells were selected by the medium containing 500 g/ml G418, and clones derived from 
single cells were picked up.  
RNA Interference Experiments Using Small Interfering RNAs (siRNAs) 
ALDH1A2 siRNA-1 (s16907) was purchased from Ambion (Life Technologies, Japan). 
K562AC cells were transfected with siRNA using Lipofectamine Reagent (Life 
Technologies, Japan). As a negative control, a scrambled oligonucleotide, Negative 
control #2 (Life Technologies, Japan), was used. At 48 h after transfection, cells were 
treated with AraC for 24 h. Cell survival was determined using MTT assay, as described 
above. 
Histopathology 
Smeared bone marrow slides were fixed with 100% methanol. The slide was treated 
with 0.3% hydrogen peroxide to block nonspecific staining. The primary antibody used 
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was rabbit anti-ALDH1A2 polyclonal antibody (Abcam, Cambridge, UK). The slide 
was incubated overnight with the antibody at 4°C. After washing in 50 mM 
Tris-buffered saline, a refined avidin-biotin technique in which a biotinylated secondary 
antibody reacts with several peroxidase-conjugated streptavidin molecules was 
employed for amplification using a DAKO LSAB+/HRP kit (Dako, Tokyo, Japan). 
Diaminobenzidine tetrahydrochloride (DAB) was used for the visualization of 
immunoreactive cells. The nuclei of cells were counterstained with hematoxylin. The 
total number of cells was counted; it was checked to determine whether the cells were 
positive or not. The ratio of positive cells to total cells was used to estimate the rate of 
ALDH1A2 positive cells. 
Clinical Case 
Peripheral blood was drawn from five patients with AraC resistance. The diagnosis of 
leukemia was based on clinical features and hematological characteristics. Ara-C 
resistance was clinically defined as follows: The case could not achieve complete 
remission (CR) by one or two courses of induction chemotherapy consisting of 12 
mg/m
2
 idarubicin [IDA] on days 1-3 and 100 mg/m
2
 Ara-C on days 1-7 and salvage 
chemotherapy with high-dose Ara-C (2000 mg/m
2
 Ara-C every 12 hours on days 1-5). 
CR was defined according to Cheson’s criteria [16]. Informed consent was obtained 
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according to the Declaration of Helsinki. The study protocol comprised a retrospective 
case series design that was approved by the institutional review board at Gifu university 
hospital. Supplement Table 1 shows the main clinical findings of all the patients studied. 
Statistical Analysis 
The results depicted in Fig. 3, Fig. 4 and Fig. 5 are expressed as means ± SD. 







The protein profiles by 2D-DIGE 
Protein expression in K562S and K562AC cells was compared using 2D-DIGE. 
AraC-resistance in K562 cells was established before, as described previously [13]. To 
confirm the resistance or sensitivity to AraC in K562S and K562AC cells, the viability 
of both cells after AraC treatment was examined using the MTT assay. After AraC 
treatment, there was no growth of K562S cells, while the proliferation of K562AC cells 
was unaffected. (Supplement Fig. 1).  
In order to identify the proteins involved in the acquisition of AraC resistance, the 
differences in protein expression in K562S and K562A were examined by DIGE and 
mass spectrometry. The total number of differentially expressed proteins identified in 
the two cell lines was 2073. Of the proteins identified, the differences in expression of 
15 proteins were found to be statistically significant (Fig. 1). These proteins were 
identified by mass spectrometry. Table 1 shows a list of the differentially expressed 
proteins with their protein accession numbers, calculated fold changes, and p values. 
The 15 proteins were assigned to four categories based on their function, namely 
macromolecular metabolism (amino acid and sugar metabolism), molecular 
cytoskeleton reorganization, signal transduction, and oxidative stress. 
14 
 
To validate the differential protein expression, RT-PCR and western blotting were 
performed for two proteins with the highest differential rate. The two proteins were 
found to be ALDH1A2 and vimentin (Fig. 2).  
Effects of ALDH1A2 on AraC resistance 
It has recently been reported that the amount of expressed ALDH isoform correlates 
with drug resistance [17] [18]. And, some reports showed that retinoic acid inhibited the 
vimentin expression [19]. We examined the expression of vimentin in K562S treated 
with retinoic acid. The retinoic acid treatment decreased the vimentin expression (data 
not shown). This result suggested that vimentin expression was controlled by 
ALDH1A2 expression. Thus, RALDH2 expression was considered to be more 
important to acquire the resistance than vimentin expression. Therefore, the effect of 
ALDH1A2 on AraC resistance in K562AC cells was investigated here. This was done 
by knocking down ALDH1A2 in K562AC cells using siRNA. ALDH1A2 knock down 
(KD) was confirmed using RT-PCR and western blotting (Fig. 3A). Cell viability was 
compared between the ALDH1A2 KD cells treated with and without AraC. The 
viability of ALDH1A2 KD cells was found to be reduced by AraC treatment. This 
shows that ALDH1A2 KD induces sensitivity to AraC in K562AC cells (Fig. 3B). To 
confirm the effect of ALDH1A2 on AraC resistance, the ALDH1A2 gene was 
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transfected to K562AS cells. The cells with this transfection acquired the resistance to 
AraC (Fig. 4). 
Immunohistochemical analysis of ALDH1A2 in AraC-Resistant Patients 
An in vitro study has suggested that ALDH1A2 may be associated with AraC resistance. 
Therefore, the expression of ALDH1A2 in the peripheral blood of AraC-resistant 
patients was examined using immunohistochemical analysis. ALDH1A2 expression in 
AraC-resistant patients was compared before and after the acquisition of resistance. Fig. 
5 shows that ALDH1A2 expression was high in patients with AraC resistance and that 







The present study reveals that 15 proteins, including ALDH1A2, present in K562AC 
cells are significantly down- or up-regulated. ALDH1A2 belongs to the aldehyde 
dehydrogenase (ALDH) family. Twelve ALDH genes have been identified in humans. 
These genes, located on different chromosomes, encode a group of enzymes which 
oxidize a variety of aliphatic and aromatic aldehydes [20, 21]. Many studies have shown 
that some ALDH family members play an important role in drug resistance [17, 18]. 
ALDH3A1 (a member of the ALDH family) expression in tumor cells has been shown 
to induce resistance to drug toxicity, resulting in a poor response to anti-tumor drugs. As 
previously reported, ALDH3A1 is associated with resistance to etoposide and 
Mitomycin C [18]. It is also known that transfection with rat ALDH3 confers 
oxazaphosphorine-specific resistance on human MCF-7 cells. The resistance is also 
known to be reversed upon pretreatment with diethylaminobenzaldehyde, an ALDH3 
inhibitor [22]. It has also been previously reported that overexpression of ALDH1A2 
induces drug resistance [17].  
ALDH1A2 is an enzyme that catalyzes the synthesis of retinoic acid from 
retinaldehyde. Retinoic acid is an active metabolite of vitamin A and regulates a wide 
range of biological processes including cell proliferation, differentiation, and 
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morphogenesis [23]. Recently, Moreb et al showed that the overexpression of both 
ALDH1A2 and ALDH2 results in increased relative resistance to both 
4-Hydroperoxycyclophosphamide (4-HC) and doxorubicin, but resistant mechanisms 
did not reveled [17]. We also examined the protein expression pattern in K562 
doxorubicin resistant cells using 2D-DIGE. 16 proteins were remarkably altered 
between K562 doxorubicin and K562S (Supplemental figure. 2). Our results showed 
that ALDH1A2 expression did not altered in K562 cell with doxorubicin resistance. The 
identified proteins were different between AraC resistance cells and doxorubicin 
resistance cells. These protein profiles revealed the participation of different proteins in 
the resistant mechanism of each two drugs. 
The results of the present study using K562AC cells suggest that the expression of 
ALDH1A2 increases in AraC-resistant cells. Furthermore, ALDH1A2 KD is found to 
induce sensitivity to AraC treatment in K562AC cells, and ALDH1A2 overexpression 
on K562S cells induced the AraC resistance. It is speculated that ALDH1A2 expression 
in K562AC cells induces the accumulation of RA in the cytosolic space. Retinoic acid 
accumulation may be involved in the anti-apoptotic property. Kitamura et al. have 
shown that retinoic acid plays a role in the signal transduction pathways involved in 
hydrogen peroxide (H2O2)-induced apoptosis [24]. H2O2 induces apoptosis in mesangial 
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cells via activation of c-Jun-N-terminal kinase (JNK) and extracellular signal-regulated 
kinase (ERK). ERK and JNK induce accumulation and activation of activator protein-1 
(AP-1), causing apoptosis. RA inhibits the apoptotic process by suppressing AP-1. This 
is because retinoic acid attenuates the expression of c-Fos/c-Jun and activation of JNK, 
at least in part, via induction of the dual-specificity protein phosphatase, MAP kinase 
phosphatase 1 (MKP-1) [25]. These findings suggest that ALDH1A2 may contribute to 
protection of drug-resistant cells from the apoptotic signaling by AraC in K562 cells. 
Further studies are still needed to verify the possible mechanisms for AraC 
resistance. However, the results of the present study provide useful insights into the 
mechanisms of drug resistance and allow us to assume that various molecules 
participate in the mechanism. It is difficult to elucidate the actual mechanism of drug 
resistance because of the up-regulation of only ALDH1A2, although it is known that 
ALDH1A2 plays an important role. Studying the interaction between ALDH1A2 and 
other molecules may be useful for the elucidation of the mechanism of AraC resistance. 
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2D-DIGE gel images of K562S labeled with Cy5 and K562AC labeled with Cy3. (A) 
Spots of proteins differentially expressed (p<0.05, fold change ≥2.0) were selected for 
identification. (B) Spots 4, 5 and 6, examples evaluated using Decyder. The top panel is 
the partial view. The middle panel is the 3D image. The bottom panel analyzed to each 
spot about relative protein abundance (Standard, K562 and K562AC). 
Figure 2.  
RT-PCR and western blotting analysis of vimentin, ALDH1A2, and GAPDH in K562S 
and K562AC. 
To validate the differing expressions of proteins in K562S and K562AC, expression of 
both ALDH1A2 and vimentin genes was observed in both cell lines. (A) RT-PCR 
showing the mRNA expressions of ALDH1A2 and vimentin in K562S and K562AC. 




Effects of AraC treatment in K562AC with ALDH1A2 KD 
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(A) ALDH1A2 KD in K562AC examined by RT-PCR and western blot. (B) 
Proliferation of K562AC with ALDH1A2 KD after AraC treatment examined using the 
proliferation assay. ALDH1A2 KD induced sensitivity to AraC. Data are shown as the 
mean ± SD of three independent experiments. *p<0.05. 
 
Figure 4. 
Effects of ALDH1A2 overexpression in K562S. 
(A) ALDH1A2 overexpression in K562S confirmed by western blot. (B) Proliferation 
of K562S with ALDH1A2 overexpressed after AraC treatment examined using the 
proliferation assay. ALDH1A2 overexpression induced resistance to AraC. Data are 
shown as the mean ± SD of three independent experiments. *p<0.001. 
 
Figure 5. 
Immunohistochemical analysis of ALDH1A2 in AraC resistant patients. 
(A) ALDH1A2 expression observed in the peripheral blood of Ara-C-resistant patients 
before and after the acquisition of AraC resistance. The results of one of the five 
analyses are shown because similar results were obtained in the five analyses (a, c: 
lower magnification, b, d: higher magnification). (B) Changes in ALDH1A2 expression 
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in leukemia cells before and after the acquisition of AraC resistance. The rate of positive 
cells in all AraC resistant patients is summarized. *p<0.05.  
 
Supplement Figure 1. 
Viability of K562S and K562AC cells after AraC treatment. 
K562S and K562AC cells were treated in the presence or absence of AraC. After 24 h, 
48 h, and 72 h of AraC treatment, proliferation was determined by the cell proliferation 
assay. The results are expressed as the mean ± SD of three independent experiments. 
 
Supplement Figure 2. 
2D-DIGE gel images of K562S labeled with Cy5 and K562DOX labeled with Cy3. (A) 









Spot no. Protein name ID (NCBI) p-value Fold change
1 Phosphoenolpyruvate carboxykinase gi290457671 0.0016 2.18
2 Syntaxin-binding protein 1 gi50403646 0.0016 2.53
3 Glucose-6-phosphate isomerase gi17380385 0.0053 -2.28
4 Aldehyde dehydrogenase 1 family, member A2 gi25777724 0.00088 11.48
5 Vimentin gi55977767 0.0016 -3.59
6 D-3-phosphoglycerate dehydrogenase gi21264510 0.0040 2.52
7 Cytokeratin-8 gi90110027 0.00097 2.73
8 hnRNP D0 gi13124489 0.0018 -2.00
9 Ornithine aminotransferase gi129018 0.00076 -2.39
10 Medium-chain specific acyl-CoA dehydrogenase gi113017 0.0023 2.63
11 Annexin A2 gi113950 0.0049 2.00
12 Glutathione S-transferase omega-1 gi6016173 0.00088 2.11
Carbonic anhydrase 2 gi115456)
Phosphoglycerate mutase 1 gi130348
14 Transgelin-2 gi586000 0.0025 2.37






1 Ezrin gi125987826 0.0640 3.19
2 Leukotriene A-4 hydrolase gi126353 0.0041 2.33
Catalase gi115702
Pyruvate kinase isozymes R/L gi8247933
4 Inosine-5'-monophosphate dehydrogenase 2 gi124419 0.0021 2.92
5 Glucose-6-phosphate 1-dehydrogenase gi116242483 0.0048 2.19
6 Lupus La protein gi125985 0.0030 2.24
7 Lupus La protein gi125985 0.0025 2.15
8 Multifunctional protein ADE2 gi131628 0.0016 2.38
9 Serpin B9 gi1709896 0.0020 -2.39
10 Reticulocalbin-1 gi2493462 0.0038 -3.43
11 Macrophage-capping protein gi313104088 0.0021 3.29
Phosphoglycerate mutase 1 gi130348
Carbonic anhydrase 2 gi115456
15-hydroxyprostaglandin dehydrogenase [NAD+] gi129889
Putative ATP-dependent Clp protease proteolytic subunit gi3023512
Kinetochore protein Spc24 gi74751176
Calbindin gi115394
15 Peroxiredoxin-1 gi548453 0.0021 2.30
16 Flavin reductase gi1706870 0.0030 2.42
17 Flavin reductase gi1706870 0.0024 2.60
18 Sorcin gi267021 0.0048 4.60
19 Sorcin gi267021 0.0066 2.12
20 Sorcin gi267021 0.0018 6.05
21 Sorcin gi267021 0.0025 2.81
22 Sorcin gi267021 0.0021 3.72
Spot no. Protein name ID (NCBI) p-value Fold change
-4.56
0.0054 2.31
0.0021 -2.52
0.0050 5.61
3
12
13
14 0.0025
